PE20070141A1 - Derivados de isoquinolina como inhibidores de rho-cinasa - Google Patents
Derivados de isoquinolina como inhibidores de rho-cinasaInfo
- Publication number
- PE20070141A1 PE20070141A1 PE2006000735A PE2006000735A PE20070141A1 PE 20070141 A1 PE20070141 A1 PE 20070141A1 PE 2006000735 A PE2006000735 A PE 2006000735A PE 2006000735 A PE2006000735 A PE 2006000735A PE 20070141 A1 PE20070141 A1 PE 20070141A1
- Authority
- PE
- Peru
- Prior art keywords
- halogen
- alkyl
- rho
- iloxi
- isoquinolin
- Prior art date
Links
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical class C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 title 1
- 239000003590 rho kinase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Gynecology & Obstetrics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA (I) DONDE R1 ES H, ALQUILO(C1-C6), NH-ALQUIL(C1-C6), ENTRE OTROS; R2 ES H, HALOGENO O ALQUILO(C1-C6); R3 ES H, HALOGENO, OH, NH2, ENTRE OTROS; R4 ES H, HALOGENO, CN, ALQUILO(C1-C6), ENTRE OTROS; R5 ES H, HALOGENO, NO2, ALQUENILO(C2-C6), ENTRE OTROS; R6 ES H, ALQUILO(C1-C8), ALQUILENO(C1-C6)-C(O)NH2, ENTRE OTROS; R7 ES H, HALOGENO, ALQUENILO(C2-C6), CN, ENTRE OTROS; R8 ES H, HALOGENO O ALQUILO(C1-C6); L ES O U O-ALQUILENO(C1-C6); n ES DE 1 A 4. SON COMPUESTOS PREFERIDOS: ESTER TERC-BUTILICO DEL ACIDO 4-(5-BROMO-ISOQUINOLIN-6-ILOXI)-PIPERIDIN-1-CARBOXILICO, ESTER TERC-BUTILICO DEL ACIDO 4-(5-CIANO-ISOQUINOLIN-6-ILOXI)-PIPERIDIN-1-CARBOXILICO, ESTER TERC-BUTILICO DEL ACIDO 4-(5-AZIDO-ISOQUINOLIN-6-ILOXI)-PIPERIDIN-1-CARBOXILICO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE RHO-CINASA SIENDO UTILES EN EL TRATAMIENTO DE HIPERTENSION PULMONAR, HIPERTENSION OCULAR, ANGINA DE PECHO, VASOESPASMO CEREBRAL
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05013868 | 2005-06-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20070141A1 true PE20070141A1 (es) | 2007-02-21 |
Family
ID=35395794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006000735A PE20070141A1 (es) | 2005-06-28 | 2006-06-26 | Derivados de isoquinolina como inhibidores de rho-cinasa |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US8501736B2 (es) |
| EP (1) | EP1899322B1 (es) |
| JP (1) | JP5097701B2 (es) |
| KR (1) | KR101327780B1 (es) |
| CN (1) | CN101213187B (es) |
| AR (1) | AR054518A1 (es) |
| AT (1) | ATE441641T1 (es) |
| AU (1) | AU2006264043B2 (es) |
| BR (1) | BRPI0613597A2 (es) |
| CA (1) | CA2611295C (es) |
| CY (1) | CY1110108T1 (es) |
| DE (1) | DE602006008945D1 (es) |
| DK (1) | DK1899322T3 (es) |
| DO (1) | DOP2006000149A (es) |
| ES (1) | ES2331853T3 (es) |
| GT (1) | GT200600273A (es) |
| HR (1) | HRP20090589T1 (es) |
| IL (1) | IL188380A (es) |
| MA (1) | MA29535B1 (es) |
| MX (1) | MX2008000017A (es) |
| MY (1) | MY146037A (es) |
| NZ (1) | NZ565040A (es) |
| PA (1) | PA8683501A1 (es) |
| PE (1) | PE20070141A1 (es) |
| PL (1) | PL1899322T3 (es) |
| PT (1) | PT1899322E (es) |
| RS (1) | RS51139B (es) |
| RU (1) | RU2443688C2 (es) |
| SI (1) | SI1899322T1 (es) |
| TW (1) | TWI372756B (es) |
| UY (1) | UY29641A1 (es) |
| WO (1) | WO2007000240A1 (es) |
| ZA (1) | ZA200710001B (es) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2024342A2 (en) * | 2006-05-01 | 2009-02-18 | Pfizer Products Incorporated | Substituted 2-amino-fused heterocyclic compounds |
| CA2673921C (en) | 2006-12-27 | 2015-10-20 | Sanofi-Aventis | New substituted isoquinoline and isoquinolinone derivatives |
| NZ577981A (en) * | 2006-12-27 | 2011-12-22 | Sanofi Aventis | Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase |
| JP5318778B2 (ja) * | 2006-12-27 | 2013-10-16 | サノフイ | シクロアルキルアミン置換イソキノロン及びイソキノリノン誘導体 |
| JP5405316B2 (ja) * | 2006-12-27 | 2014-02-05 | サノフイ | シクロアルキルアミン置換イソキノリン誘導体 |
| GB0719644D0 (en) | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB0803018D0 (en) * | 2008-02-19 | 2008-03-26 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| KR101638326B1 (ko) * | 2008-06-24 | 2016-07-12 | 사노피 | Ｒｈｏ 키나제 억제제로서의 치환된 이소퀴놀린 및 이소퀴놀리논 |
| MX2010013867A (es) * | 2008-06-24 | 2011-02-24 | Sanofi Aventis | Derivados de isoquinolina e isoquinolinona bi- y policiclicos sustituidos. |
| MX2010013974A (es) * | 2008-06-24 | 2011-01-14 | Sanofi Aventis | Isoquinolinas e isoquinolinonas 6-sustituidas. |
| GB0812969D0 (en) | 2008-07-15 | 2008-08-20 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| BRPI0919282A2 (pt) * | 2008-10-02 | 2017-03-28 | Asahi Kasei Pharma Corp | composto, composição farmacêutica, inibidor de ikkb, método para inibir ikkb, métodos para prevenir e/ou tratar uma doença ou sintoma associado com nf-kb, uma doença ou sintoma associado com ikkb, e uma doença ou sintoma associado com reação inflamatória aguda ou crônica em mamíferos |
| EP2177218A1 (en) | 2008-10-15 | 2010-04-21 | Medizinische Universität Wien | Regenerative therapy |
| JP5391372B2 (ja) * | 2009-07-08 | 2014-01-15 | 公益財団法人名古屋産業科学研究所 | 芳香族アミン化合物の製造方法 |
| BR112012024705A2 (pt) * | 2010-03-31 | 2016-06-07 | Actelion Pharmaceuticals Ltd | derivados antibacterianos de isoquinolin-3-ilureia |
| JP6026427B2 (ja) | 2010-12-17 | 2016-11-16 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 置換６，６−縮合窒素複素環化合物及びその使用 |
| GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| BR112014010938A2 (pt) | 2011-11-09 | 2017-05-16 | Cancer Res Tech Ltd | compostos de 5-(piridin-2-il-amino)-pirazina-2-carbonitrila e seu uso terapêutico |
| KR102341637B1 (ko) | 2012-05-15 | 2021-12-21 | 캔써 리서치 테크놀로지 리미티드 | 5-[[4-[[모르폴린-2-일]메틸아미노]-5-(트리플루오로메틸)-2-피리딜]아미노]피라진-2-카보니트릴 및 그의 치료적 용도 |
| GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
| GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
| JP6461150B2 (ja) | 2013-07-31 | 2019-01-30 | ノバルティス アーゲー | １，４−二置換ピリダジン誘導体およびｓｍｎ欠損に関連する状態を処置するためのその使用 |
| FR3017868A1 (fr) * | 2014-02-21 | 2015-08-28 | Servier Lab | Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| GB201403536D0 (en) | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
| TWI699355B (zh) | 2014-12-24 | 2020-07-21 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
| BR112017013440A2 (pt) | 2014-12-24 | 2018-01-09 | Gilead Sciences, Inc. | compostos de isoquinolina para o tratamento de hiv |
| MX2017008520A (es) | 2014-12-24 | 2018-03-01 | Gilead Sciences Inc | Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih). |
| WO2018183964A1 (en) | 2017-03-30 | 2018-10-04 | Genentech, Inc. | Isoquinolines as inhibitors of hpk1 |
| GB201709840D0 (en) | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
| US10696638B2 (en) | 2017-12-26 | 2020-06-30 | Industrial Technology Research Institute | Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same |
| CN110117278B (zh) * | 2018-02-07 | 2022-07-19 | 石家庄以岭药业股份有限公司 | 烷氧基苯并五元(六元)杂环胺类化合物及其药物用途 |
| EP3801500B1 (en) * | 2018-06-07 | 2025-03-05 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| CN112601584A (zh) * | 2018-07-24 | 2021-04-02 | 豪夫迈·罗氏有限公司 | 异喹啉化合物及其用途 |
| TW202024053A (zh) | 2018-10-02 | 2020-07-01 | 美商建南德克公司 | 異喹啉化合物及其用途 |
| US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
| CN110407777B (zh) * | 2019-08-15 | 2022-09-09 | 湖北远大富驰医药化工股份有限公司 | 一种呋虫胺的合成方法 |
| CN111574413B (zh) * | 2020-06-08 | 2022-04-05 | 杭州尚合生物医药科技有限公司 | 一种2-氨甲基吡啶与dmf-dma作为胺源的磺酰脒的制备方法 |
| CN113372341A (zh) * | 2021-07-02 | 2021-09-10 | 黄淮学院 | 三氟醋酸二氢异喹啉衍生物的合成方法及装置 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2485537B2 (fr) | 1977-04-13 | 1986-05-16 | Anvar | Dipyrido(4,3-b)(3,4-f)indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant |
| JPH06501921A (ja) | 1990-07-31 | 1994-03-03 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 選択されたハロカーボンの触媒平衡化 |
| US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| GB9516709D0 (en) | 1995-08-15 | 1995-10-18 | Zeneca Ltd | Medicament |
| ZA9610741B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
| EP0956865B2 (en) * | 1996-08-12 | 2010-08-18 | Mitsubishi Tanabe Pharma Corporation | MEDICINES COMPRISING Rho KINASE INHIBITOR |
| JPH1087629A (ja) | 1996-09-18 | 1998-04-07 | Fujisawa Pharmaceut Co Ltd | 新規イソキノリン誘導体、およびその医薬用途 |
| AU8872198A (en) | 1997-08-29 | 1999-03-22 | Zeneca Limited | Aminometyl oxooxazolidinyl benzene derivatives |
| TW575567B (en) | 1998-10-23 | 2004-02-11 | Akzo Nobel Nv | Serine protease inhibitor |
| GB9912701D0 (en) | 1999-06-01 | 1999-08-04 | Smithkline Beecham Plc | Novel compounds |
| US6541456B1 (en) | 1999-12-01 | 2003-04-01 | Isis Pharmaceuticals, Inc. | Antimicrobial 2-deoxystreptamine compounds |
| BR0107732A (pt) | 2000-01-20 | 2003-03-11 | Eisai Ltd | Método para prevenir ou tratar uma doença |
| US7217722B2 (en) | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
| WO2001064238A2 (en) | 2000-02-29 | 2001-09-07 | Curis, Inc. | Methods and compositions for regulating adipocytes |
| GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
| GB0013060D0 (en) | 2000-05-31 | 2000-07-19 | Astrazeneca Ab | Chemical compounds |
| AU2001296008A1 (en) | 2000-10-27 | 2002-05-06 | Takeda Chemical Industries Ltd. | Process for preparing substituted aromatic compounds and intermediates therefor |
| WO2002055496A1 (en) | 2001-01-15 | 2002-07-18 | Glaxo Group Limited | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression |
| MY134783A (en) | 2001-03-23 | 2007-12-31 | Bayer Healthcare Llc | Rho-kinase inhibitors |
| SE0101038D0 (sv) | 2001-03-23 | 2001-03-23 | Astrazeneca Ab | Novel compounds |
| WO2002088101A2 (en) | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of bace |
| EP1403255A4 (en) | 2001-06-12 | 2005-04-06 | Sumitomo Pharma | RHO KINASE INHIBITORS |
| GB0117899D0 (en) | 2001-07-23 | 2001-09-12 | Astrazeneca Ab | Chemical compounds |
| WO2003024450A1 (en) | 2001-09-20 | 2003-03-27 | Eisai Co., Ltd. | Methods for treating prion diseases |
| SE0104340D0 (sv) | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New compounds |
| EP1541559A4 (en) * | 2002-07-22 | 2007-08-22 | Asahi Kasei Pharma Corp | 5-SUBSTITUTED ISOQUINOLINE DERIVATIVE |
| US7615564B2 (en) | 2002-09-12 | 2009-11-10 | Kirin Beer Kabushiki Kaisha | Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same |
| WO2004105757A2 (en) | 2003-05-29 | 2004-12-09 | Schering Aktiengesellschaft | Use of rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy |
| WO2004113297A2 (en) | 2003-06-24 | 2004-12-29 | Neurosearch A/S | Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| EP1667982B1 (en) | 2003-09-23 | 2013-07-31 | Merck Sharp & Dohme Corp. | Isoquinolinone potassium channel inhibitors |
| AU2004275720B2 (en) | 2003-09-23 | 2008-04-24 | Merck Sharp & Dohme Corp. | Isoquinoline potassium channel inhibitors |
| US20050067037A1 (en) | 2003-09-30 | 2005-03-31 | Conocophillips Company | Collapse resistant composite riser |
| EP1671962A1 (en) | 2003-10-10 | 2006-06-21 | Ono Pharmaceutical Co., Ltd. | Novel fused heterocyclic compound and use thereof |
| WO2005054202A1 (en) | 2003-11-25 | 2005-06-16 | Eli Lilly And Company | 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b) |
| JP2005232175A (ja) * | 2004-01-21 | 2005-09-02 | Asahi Kasei Pharma Kk | ５−置換イソキノリン医薬 |
| WO2005074535A2 (en) | 2004-01-30 | 2005-08-18 | Eisai Co., Ltd. | Cholinesterase inhibitors for spinal cord disorders |
| EP1729761A4 (en) | 2004-03-05 | 2008-09-03 | Eisai Co Ltd | TREATMENT OF CADASIL WITH CHOLINESTERASE INHIBITORS |
| SE0400850D0 (sv) | 2004-03-30 | 2004-03-31 | Astrazeneca Ab | Novel Compounds |
| US7517991B2 (en) | 2004-10-12 | 2009-04-14 | Bristol-Myers Squibb Company | N-sulfonylpiperidine cannabinoid receptor 1 antagonists |
| EP2385047B1 (en) | 2005-07-26 | 2013-05-29 | Sanofi | Piperidinyl-substituted isoquinolone derivatives |
| NI200800024A (es) | 2005-07-26 | 2009-03-03 | Derivados de ciclohexilaminisoquinolona en calidad inhibidores de rho-quinasa | |
| TW200745101A (en) | 2005-09-30 | 2007-12-16 | Organon Nv | 9-Azabicyclo[3.3.1]nonane derivatives |
| JP4033221B2 (ja) | 2005-12-02 | 2008-01-16 | ダイキン工業株式会社 | 冷媒加熱装置 |
| US7618985B2 (en) | 2005-12-08 | 2009-11-17 | N.V. Organon | Isoquinoline derivatives |
| TW200738682A (en) | 2005-12-08 | 2007-10-16 | Organon Nv | Isoquinoline derivatives |
| US7893088B2 (en) | 2006-08-18 | 2011-02-22 | N.V. Organon | 6-substituted isoquinoline derivatives |
| CA2673921C (en) | 2006-12-27 | 2015-10-20 | Sanofi-Aventis | New substituted isoquinoline and isoquinolinone derivatives |
| RU2468011C2 (ru) | 2006-12-27 | 2012-11-27 | Санофи-Авентис | Замещенные циклоалкиламином производные изохинолина и изохинолинона |
-
2006
- 2006-06-13 PT PT06754323T patent/PT1899322E/pt unknown
- 2006-06-13 NZ NZ565040A patent/NZ565040A/en not_active IP Right Cessation
- 2006-06-13 CA CA2611295A patent/CA2611295C/en not_active Expired - Fee Related
- 2006-06-13 DE DE602006008945T patent/DE602006008945D1/de active Active
- 2006-06-13 WO PCT/EP2006/005648 patent/WO2007000240A1/en not_active Ceased
- 2006-06-13 HR HR20090589T patent/HRP20090589T1/hr unknown
- 2006-06-13 RS RSP-2009/0516A patent/RS51139B/sr unknown
- 2006-06-13 EP EP06754323A patent/EP1899322B1/en active Active
- 2006-06-13 DK DK06754323T patent/DK1899322T3/da active
- 2006-06-13 SI SI200630484T patent/SI1899322T1/sl unknown
- 2006-06-13 PL PL06754323T patent/PL1899322T3/pl unknown
- 2006-06-13 BR BRPI0613597-8A patent/BRPI0613597A2/pt not_active IP Right Cessation
- 2006-06-13 AU AU2006264043A patent/AU2006264043B2/en not_active Ceased
- 2006-06-13 CN CN2006800238102A patent/CN101213187B/zh not_active Expired - Fee Related
- 2006-06-13 AT AT06754323T patent/ATE441641T1/de active
- 2006-06-13 MX MX2008000017A patent/MX2008000017A/es active IP Right Grant
- 2006-06-13 RU RU2008102968/04A patent/RU2443688C2/ru not_active IP Right Cessation
- 2006-06-13 ES ES06754323T patent/ES2331853T3/es active Active
- 2006-06-13 JP JP2008518659A patent/JP5097701B2/ja not_active Expired - Fee Related
- 2006-06-13 KR KR1020077030517A patent/KR101327780B1/ko not_active Expired - Fee Related
- 2006-06-26 TW TW095122877A patent/TWI372756B/zh not_active IP Right Cessation
- 2006-06-26 GT GT200600273A patent/GT200600273A/es unknown
- 2006-06-26 DO DO2006000149A patent/DOP2006000149A/es unknown
- 2006-06-26 PE PE2006000735A patent/PE20070141A1/es not_active Application Discontinuation
- 2006-06-26 AR ARP060102738A patent/AR054518A1/es unknown
- 2006-06-27 MY MYPI20063032A patent/MY146037A/en unknown
- 2006-06-27 PA PA20068683501A patent/PA8683501A1/es unknown
- 2006-06-29 UY UY29641A patent/UY29641A1/es unknown
-
2007
- 2007-11-20 ZA ZA200710001A patent/ZA200710001B/xx unknown
- 2007-12-07 MA MA30457A patent/MA29535B1/fr unknown
- 2007-12-20 US US11/961,193 patent/US8501736B2/en not_active Expired - Fee Related
- 2007-12-24 IL IL188380A patent/IL188380A/en not_active IP Right Cessation
-
2009
- 2009-11-25 CY CY20091101226T patent/CY1110108T1/el unknown
-
2011
- 2011-06-15 US US13/160,983 patent/US8722671B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20070141A1 (es) | Derivados de isoquinolina como inhibidores de rho-cinasa | |
| PE20070808A1 (es) | COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA | |
| PE20061106A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| PE20070217A1 (es) | Derivados de isoquinolona sustituidos con piperidinilo | |
| PE20141075A1 (es) | 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina | |
| PE20091466A1 (es) | Derivados de 4,5-dihidro-oxazol-2-il-amina | |
| PE20070181A1 (es) | DERIVADOS DE CICLOHEXILAMINISOQUINOLONA COMO INHIBIDORES DE Rho-QUINASA | |
| PE20091734A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| PE20120620A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
| PE20121640A1 (es) | Derivados de pirazina como inhibidores de bace | |
| PE20090649A1 (es) | DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1 | |
| PE20121282A1 (es) | Antagonistas de espiro-oxindol de mdm2 | |
| EA201101398A1 (ru) | Замещенные пиперидины в качестве антагонистов ccr3 | |
| PE20090276A1 (es) | Compuestos derivados de imidazoquinolina como moduladores de tlr7 | |
| PE20061439A1 (es) | DERIVADOS DE 2-AMIDO-6-AMINO-8-OXO-PURINA COMO MODULADORES DEL RECEPTOR Toll (TLR) | |
| PE20071061A1 (es) | Derivados de carbonilo como inhibidores de peptidil-deformilasa (pdf) | |
| PE20060777A1 (es) | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas | |
| PE20080552A1 (es) | Derivados de alcoholes 1-fenil-2-piridinil alquilenicos como inhibidores de fosfodiesterasa | |
| ATE554085T1 (de) | Neue inhibitoren von glutaminylcyclase | |
| PE20060298A1 (es) | Derivados de acido carboxilico de bencimidazolona | |
| ATE463483T1 (de) | 6-substituierte isochinolinderivate als rock-1- inhibitoren | |
| CO6270285A2 (es) | Derivados de 4-[(4-amino-1, 3, 5-triazin-2-il)amino]-n-arilmetilcicloalquilcarboxamida | |
| PE20060589A1 (es) | FENILAMINOTIAZOLES SUSTITUIDOS COMO AGONISTAS DE ADENOSINA A1 Y A2b | |
| PE20100155A1 (es) | Derivados de urea heterociclicos y metodos de uso de los mismos-332 | |
| ATE404536T1 (de) | Substituierte chinolinderivate als inhibitoren von mitotischem kinesin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |